11
Participants
Start Date
April 30, 2010
Primary Completion Date
March 31, 2013
Study Completion Date
January 31, 2016
azacitidine
Azacitidine 75 mg/m2 SC or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a.
lenalidomide
Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1.
Duke University Medical Center, Durham
Lead Sponsor
Collaborators (1)
Celgene
INDUSTRY
Duke University
OTHER